The 12th International Meeting on Human Genome Variation and Complex Genome Analysis (HGV2011: Berkeley, California, USA, 8th-10th September 2011) was a stimulating workshop where researchers from academia and industry explored the latest progress, challenges, and opportunities in genome variation research. Key themes included progress beyond GWAS, variation in human populations, use of sequence data in medical settings, large-scale sequencing data analysis, and bioinformatics approaches to large datasets.
Introduction
The 12th International Meeting on Human Genome Variation and Complex Genome Analysis (HGV2011), held 8th-10th September 2011 in Berkeley, California, USA, was attended by 180 participants from 30 countries around the world. HGV2011 featured the description of several real-world clinical applications of genomic medicine, ongoing discussions of the contributions of swaths of genomic data to studies of human disease, and both cautions as well as suggestions for improvements to the technology and methods used to identify meaningful human variation.
In keeping with meeting tradition, all participants presented original work at HGV2011, with 34 oral presentations interspersed with >140 poster presentations. With a limited meeting size and ample time allotted for discussion, the meeting facilitated ongoing and new interactions among participants. A new feature of HGV2011 was two interactive sessions for trainees. Orli Bahcall, Senior Editor at Nature Genetics, coached students and postdoctoral researchers on scientific publishing in high impact journals while Lisa Brooks, Program Director at the National Human Genome Research Institute (NHGRI) of the U.S. National Institutes of Health (NIH), described funding mechanisms for young investigators and how to prepare the most competitive applications for NIH funding.
The meeting program, abstracts, and more detailed information about the conference can be found at the meeting website (http://www.hgvmeeting.org/hgv2011/) and in the Supporting Materials. Online resources presented during the conference are summarized in Table 1 .
If it were possible to summarize the theme of HGV2011, it would be a dichotomy between unimaginable progress and challenging obstacles. Great progress was apparent in the production of genotypes and sequences from thousands of individuals along with research into phenotypes ranging from somatic cancers to heritable genetic diseases and the biology of aging. But, the excitement of all of these data was tempered by presentations highlighting the considerable biases and complexity that still exist in confidently identifying neutral and causal variants. A theme of cautious optimism was introduced by the first speaker, Isaac Kohane, who opened the meeting with a funny but thought-provoking analysis of how to avoid running aground in the shoals of the "incidentalome"-a term coined to point out that, with such an abundance of data, even very low rates of false positives may result in multiple, incidental, and inaccurate, discoveries.
Personalized Medicine Within Reach
Personalized medicine has been promised as a centerpiece of medical care in the future, since the publication of the human genome sequence and it may become a reality if certain conditions are met. If Yusuke Nakamura has his say, tabletop clinical instruments, with the ability to genotype and analyze patient samples in less than 45 min will soon be available in hospitals around Japan. Nakamura introduced the "Biobank Japan" project, and an exciting description of how Japan is working towards the actualization of personalized medicine, beginning with more than 320,000 samples from approximately 200,000 unique individuals, with the capability to store a combined 4 million DNA and serum samples. Biobank Japan has already identified immune-response genes involved in adverse drug reactions.
In another large-scale effort studying 30,000 Japanese, Yukinori Okada assessed interactions between inflammation-related traits. The project has had initial success in identifying mutations associated with a number of adverse drug reactions. Continuing with enormous datasets, Neil Risch presented a preliminary report on the genetic analysis of a healthcarebased cohort of 100,000 (aiming to increase to 500,000) individuals with extensive clinical, dietary, environmental, and bio specimen data, in an effort to study adult health, and aging. This project includes several thousand individuals from minority populations and the researchers are taking special care to design their experimental assays to be sensitive to population-specific differences. A huge benefit will be the opportunity to study aging in healthy individuals alongside those with disease phenotypes.
Genetic Counseling Limited by Data, and Public Understanding
Genetic counselor Heather Hampel presented the clinical challenges of interpreting sequence variations. She detailed the frustration of counselors and patients alike with sequence variants, whose biological significance or relevance to a disease are currently unknown or poorly characterized. At Ohio State University, Hampel and colleagues are investigating some of these variants of unknown significance in more detail, but she warns that many genetic counseling agencies do not have this luxury and so must rely on the sometimes vague or uninformative results returned to them by commercial agencies. Kym Boycott shared the current successes made by FORGE Canada, a nation-wide effort (including every clinical geneticist in the country) to identify genes causing rare pediatric or developmental diseases. FORGE (Finding Of Rare disease GEnes) has so far been able to determine the disease-causing mutations and offer clinical tests (such as prenatal testing) in a matter of weeks, rather than years. This research leads to discoveries that inform patients about the likelihood of a disease, but not always how to treat it. Some patients, however, prefer to only be notified of genetic predispositions that they can actively work to prevent or treat. Jill Davies discussed a model from an executive health clinic in Canada, presenting this exact take on personal genome testing in standard genetic practice, where only mutations associated with actionable recommendations are even analyzed.
How to Make Human Genome Variation Data Accessible
The gap between research and healthcare activities grows each year as scientists continue to make larger and more detailed discoveries, but fail to transmit these findings to clinicians. Robert Free introduced the audience to GWAS Central, an advanced database for the integration and comparative interrogation of genome wide association study datasets. This database includes positive as well as negative results to build a complete picture of the previous research, but faces the challenge that many research groups presently refuse to openly share extensive aggregate data (e.g., nondirectional P-values) that would not compromise research subject privacy. The website features a powerful graphical user interface and is working to make bulk downloads a reality in the near future. Anthony Brookes submitted his view on how to bridge the divide between research and healthcare informatics in the context of genotype-phenotype relationships, based on the GEN2PHEN project. This includes domain specific "Knowledge Portals" to integrate data, expert opinions, and algorithms, and the "Café Variome" data announcement service to enable safe discovery of sensitive information. He also pointed the audience towards the new Locus Reference Genomic (LRG) sequence standard that, since it avoids version updates, provides a completely stable and unambiguous means for specifying mutated nucleotides, and further proposed the adoption of unique, permanent researcher IDs from The Open Researcher and Contributor ID (ORCID) initiative to solve the name ambiguity problem in modern research.
Stephen Chanock focused on the need to improve the application of GWAS, claiming that there are, as yet, no clinical implications of GWAS hits for successfully predicting patient survival or disease outcome in cancer. His group is also developing an imputation reference set, using over 930 samples from diverse human populations, to appear in dbGaP soon that will include genotype data from nearly all commercial arrays. Russ Altman continued this theme by highlighting the prediction of both drug efficacy and adverse events in a pharmacogenetic annotation of whole genomes, to assist clinicians in understanding how genetic variation impacts drug response phenotypes, and allowing them to act on it.
In situations where a variant has been detected, one way researchers can find out more is to query MedSavant, a platform described by Michael Brundno for identifying causal variants from disease sequencing studies that aims to integrate results from across studies. Nicholas Eriksson provided an update on the initial results from the 23andMe project, with more than 100,000 individuals having been genotyped, about 60% of whom completed unsupervised surveys resulting in data on over 1,100 phenotypes. Although many correlations relating to human health and disease were presented (e.g., genetic associations with breast size that suggest shared genetic etiology with breast cancer), perhaps the most striking aspect of this presentation was that it generated a spirited debate on methodological issues related to selfreported survey results in the post-talk questions.
More Genomes, More Questions for Association Studies
Genome-wide association studies aim to correlate sequence variation with disease or other phenotypes, and have been a focus of the HGV meetings from their inception. GWAS discussed this year involved more individuals, more phenotypes, more sequence data, and more types of variation. Carlos Bustamante pointed out that 96% of the samples used in GWAS studies to date had been in individuals of European descent. He went on to describe an experiment testing human pigmentation diversity by studying the genetic variation that underlined blonde hair in the Solomon Islands (sneak peek: it is not admixture from Europeans!). Given evidence for abundant variation in relatively isolated populations, the drive is stronger than ever to study variation across many different populations. Roseann Peterson presented a combined single nucleotide polymorphism (SNP) and copy number variant (CNV) analysis for finding associations between both common and rare variants and body mass index (BMI).
Susan Walker presented efforts towards gaining a higher resolution picture of Autism Spectrum Disorder by using new exome sequencing to identify small variants and combining this with CNV analysis. David Valle noted that there were a striking number of CNVs that overlapped between autism and schizophrenia phenotypes that had not yet been explained and showed that, because advanced paternal age was a risk factor for the latter, the current data indicated that new mutations might play a large role in the development of schizophrenia.
Christina Curtis presented evidence for additional subtypes of breast cancer based on integrated genomic analyses. Ana-Teresa Maia described an efficient way to select SNPs for further investigation based on differential allelic expression using examples from breast cancer GWAS. Rounding out discussions of how to identify disease-related loci, both Judy Cho, with data on immune response in inflammatory bowel disease, and Snehit Prabhu, using theory, made the argument that understanding gene-gene interactions could greatly improve the ability to discover which genes were likely to be associated with the diseasephenotype of interest.
Population Variation Yields Insight into Human History
Thousands of individual genomes have now been sequenced, and hundreds of thousands have been genotyped, affording an unprecedented opportunity to investigate human history in novel ways. Focusing on one population and based on sequencing of Icelandic genomes, Augustine Kong brought attention to the stochastic nature of mutations, such as the wide variation in observed versus expected relatedness between family members, even siblings. Gabor Marth gave an update on variant detection in the 1000 Genomes Project, which is on track to sequence 2,500 individuals with the aim to discover 95% of variation that occurs with > 1% frequency (the 4× coverage used in this project will miss most variants with lower frequency than this). He highlighted multinucleotide polymorphism (MNP), referring to contiguous substitutions spanning more than one nucleotide, and announced that the 1000 Genomes Project is working towards an integrated map of the many different types of variation across the populations studied. From the 1000 Genomes pilot data, Sol Katzman noted that ongoing GC-biased evolution was, indeed, widespread in the human genome and was enriched near recombination hotspots. Selective sweeps driven by strong positive selection, however, seems to have been rare in recent human evolution, as presented by Ryan Hernandez. The autosomes, argued Jeff Wall, show evidence for extensive admixture (from competing ancient human groups such as African hominims and Neandertal) across all human populations. The Y chromosome, which evolves without the influences of homologous recombination, was used by Li Jin to study dispersal of human populations across the earth. Most striking is the supposition that the Y chromosomes of as many as 40% of Han Chinese may be descended from only three men that lived ~ 6,000 years ago. Understanding the underlying variation within and between human populations, especially as it results from demographic history, is necessary in association studies to identify signals attributed by population history, versus those that are related to the phenotypes of interest.
Complexity Confounds Identification of Functionally Important Regions
Study after study reminds us that the human genome is more complex than its 3 billion base pairs might imply, and so identifying functionally important variation is not always straightforward. RNA transcripts add complexity to the picture in two ways. First, events such as RNA editing, which alters RNA sequences from the underlying DNA sequences, may confound DNA-based studies. Isabel Wang showed that there were many sites in the genome where RNA sequences differed from the template DNA; they found that these RNA-DNA differences (RDD) were within coding regions and led to protein sequences not encoded by the DNA. Second, Jonathan Mudge reported that the sheer abundance of alternatively spliced transcripts can make it quite challenging to study variation in gene expression across species, especially when it is clear that many pseudogenes produce transcripts. Most strikingly, as Kirk Lohmueller and Len Pennacchio both presented, not all functionally important regions are conserved across vertebrates, or even across mammals. Lohmueller shared that, by correlating average human-chimp divergence with the minor allele frequency (MAF), one can find many sites under negative selection in the human lineage that would have escaped notice using comparative genomics approaches. Further, Pennacchio explained that heart-specific enhancers were not only poorly conserved across mammals, but those used in early development might differ from those used later in life, supporting the need for functional genomics studies to identify biologically important sequences outside of coding regions. Acknowledging these challenges opens the door to even more detailed discoveries of how genome sequences vary across individuals.
Conclusions Hinge on the Ability to Confidently Detect Variants
As the time and cost required to identify genomics variants plummets, researchers are finding themselves inundated with genomic data that they assume are accurate. Certainly small errors may exist, but even an error rate of 1 in 10,000 can drastically impact the analyses of billions of base pairs. In an effort to avoid false positives in genotyped data, Sebastian Zöllner described a coalescent model to improve methods for imputation (using haplotype maps to estimate SNPs that were not specifically typed). However, there is also a need for high-fidelity sequencing and alignments. Pui-Yan Kwok shared novel methods for long-range optical mapping for de novo sequencing assembly and CNV analysis using nanochannels for stretching long DNA molecules labeled at specific sequence motifs and fluorescent imaging, gaining high fidelity with 10× coverage of the genome. Given the popularity of short-read next generation sequencing, it might be a little disheartening to learn of systematic errors in the assembly of such sequences, as presented by Lior Pachter. But, to end on a positive note, he presented a probabilistic model and software called eXpress that may sidestep these biases, and, with its memory-light requirements, he suggested that it might soon be possible to use streaming algorithms to process highthroughput sequence data on a laptop.
The Future of Human Genome Variation
As technology for obtaining and analyzing data changes at an accelerating pace, so too will the breadth and depth of research expand. Based on a postmeeting survey of HGV2011 participants, there is a continual need and desire amongst researchers to regularly meet and discuss issues such as where human variations came from, their distribution across populations, their relationship with various phenotypes, their implications for medicine and personal health. Planning for HGV2012 is therefore underway, and it will be held in the fall in Shanghai, China.
